Panacea Biotec Awarded ₹20.79 Crore Vaccine Supply Contract

Panacea Biotec Limited has announced it has received a Letter of Award (LOA) from the Central Medical Services Society (CMSS) for the supply of Diphtheria and Tetanus Vaccine (Absorbed) for Adults and Adolescents IP.
The total value of this awarded contract is INR 20.79 Crore, with supplies scheduled to commence in tranches from September/October 2026 and conclude by November/December 2028.
Reader Takeaway: Government vaccine order secured; long supply period presents execution challenge.

What just happened (today’s filing)

Panacea Biotec announced on April 11, 2026, that it received a Letter of Award (LOA) from the Central Medical Services Society (CMSS).

The LOA is for supplying Diphtheria and Tetanus Vaccine (Absorbed) for Adults and Adolescents IP.

The contract is valued at ₹20.79 Crore and the supply period is extensive, scheduled from September/October 2026 to November/December 2028.

Why this matters

This award provides Panacea Biotec with a confirmed revenue stream of ₹20.79 Crore over approximately two years.

It signifies the company's capability to win contracts from government healthcare procurement agencies like CMSS, potentially opening doors for future government business.

The backstory (grounded)

Panacea Biotec has a track record of securing vaccine supply orders from government entities and UN agencies.

For instance, in late 2012, the company received a government order worth ₹187.61 crore for polio vaccines.

More recently, in October 2025, Panacea Biotec announced a ₹127.20 crore order from CMSS for bivalent oral polio vaccine and a long-term agreement with UNICEF for polio vaccines spanning 2026-2030.

In 2011, the company faced a temporary setback when some hepatitis vaccines were removed from the WHO prequalified list due to quality issues, but these were resolved by early 2012.

CMSS is a key government agency that procures medical supplies for public health programs in India.

What changes now

• Panacea Biotec gains a significant confirmed order bolstering its order book.
• The award reinforces its credibility in supplying vaccines to government bodies.
• Revenue from this contract will be recognized over a two-year period, contributing to financial performance.
• It highlights the company's manufacturing capacity and quality compliance for large-scale government tenders.

Risks to watch

• Delays in supply tranches, between September 2026 and December 2028, could impact revenue recognition timelines.
• Timely fulfillment of supply obligations as per the LOA is crucial for revenue realization.
• Continuous compliance with specific quality standards and regulatory requirements for vaccine supply to CMSS is mandatory.

Peer comparison

Panacea Biotec competes in a robust Indian vaccine market alongside major players like:

• Serum Institute of India, the world's largest vaccine manufacturer by volume.
• Bharat Biotech, known for its innovative vaccines like Covaxin.
• Biological E. Limited, strong in pediatric vaccines.
• Zydus Lifesciences Ltd., another key pharmaceutical and vaccine producer.

These companies also frequently participate in government tenders for vaccine supplies.

Context metrics (time-bound)

• N/A

What to track next

• Commencement of supplies as per schedule from September/October 2026.
• successful execution of all supply tranches within the stipulated period.
• Panacea Biotec's ability to secure further government and institutional tenders.
• updates on the company's overall vaccine pipeline and manufacturing capacity utilization.